

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zylox-Tonbridge Medical Technology Co., Ltd.

歸創通橋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2190)

VOLUNTARY ANNOUNCEMENT

UNAUDITED OPERATING STATISTICS FOR THE PERIOD FROM JANUARY 1, 2021 TO JUNE 30, 2021

This announcement is made by Zylox-Tonbridge Medical Technology Co., Ltd. (the “**Company**”, together with its subsidiary, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and product development progress of the Group. The board of directors (the “**Board**”) of the Company is pleased to announce certain unaudited operating statistics of the Group for the six months ended June 30, 2021.

The unaudited total revenue of the Group for the six months ended June 30, 2021 is expected to be within the range from RMB67.500 million to RMB71.500 million, representing an increase in the range of 3,102% to 3,292% from the total revenue of approximately RMB2.108 million (unaudited) for the same period of 2020. The increase in total revenue was mainly because:

- (i) since June 30, 2020, we have obtained approvals from National Medical Products Administration for eight products as of today, among which we have successfully launched six products in China as of June 30, 2021. Those launched products, mainly including Thrombite Clot Retriever Device, Ultrafree™ Drug Coated PTA Balloon Catheter, Intracranial Support Catheter and Intracranial PTA Balloon Catheter, contributed more than 85% of total revenue for the six months ended June 30, 2021;
- (ii) the sales revenue from products approved before June 30, 2020, including PTA Balloon Catheter, increased by more than 300% for the six months ended June 30, 2021, as compared to the same period of 2020; and
- (iii) we achieved significant progress in the commercialization of our products in China and covered over 1,500 hospitals via our extensive distribution network.

The Company is still in the process of finalizing the interim results of the Group for the six months ended June 30, 2021. The operating statistics disclosed above are unaudited and based on the preliminary internal information of the Group, which may be subject to change and may differ from the figures to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company on an annual or half-yearly basis due to various uncertainties during the process of collating such operating information. Such information has not been audited or reviewed by the auditors of the Company or the audit committee of the Board. They shall not be taken as a measure or indication of the Group's current or future operating or financial performance nor shall they be taken as a representation by the Group of the corresponding figures as may be provided in due course in the Group's audited or unaudited consolidated financial statements. As such, the above statistics are provided for investors' reference only. Shareholders of the Company and potential investors are advised not to place any reliance on the information disclosed herein but to exercise due caution when dealing in the securities of the Company. When in doubt, shareholders of the Company and potential investors are advised to seek professional advice from professional or financial advisers.

By order of the Board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, August 2, 2021

As of the date of this announcement, the Board of the Company comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive directors, Mr. Stephen Hui Wang, Dr. Hai Lu and Dr. Steven Dasong Wang as non-executive directors, and Dr. Jian Ji, Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive directors.